{"classes":[{"categories":[{"measurements":[{"comment":"Prior to receiving olaparib so not calculated","groupId":"OG000","spread":"NA","value":"NA"}]}],"title":"Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"312.2","value":"3.26"}]}],"title":"Day 1 - 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.5","value":"0.92"}]}],"title":"Day 15 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.8","value":"5.12"}]}],"title":"Day 15 - 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"179.0","value":"0.94"}]}],"title":"Day 29 - Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"description":"To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Taken orally twice daily","id":"OG000","title":"Olaparib 300mg Tablets"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) Analysis Set - all patients who receive study treatment as per protocol, do not violate or deviate from the protocol in ways that would significantly affect the PK analyses and have valid PK data.\n\nThe PK Analysis Set is a subset of the Global FAS; PK analysis was not performed in the China Cohort.","reportingStatus":"POSTED","timeFrame":"Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose & 1 hour; Day 15 pre-dose & 1 hour; Day 29 pre-dose. Assessed until 19 Sep 2016 DCO.","title":"To Determine the Exposure to Olaparib by Pharmacokinetic Analysis","type":"SECONDARY","unitOfMeasure":"mcg/mL"}